Apalutamide-d3

• Description:

  Apalutamide-d3 is the deuterium labeled Apalutamide[1]. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[2].

• Product Name Alternative:

  ARN-509-d3

• UNSPSC:

  12352005

• Target:

  Androgen Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2(CCC2)N(C3=CC(F)=C(C=C3)C(NC([2H])([2H])[2H])=O)C(N1C4=CN=C(C#N)C(C(F)(F)F)=C4)=S

• Molecular Formula:

  C21H12D3F4N5O2S

• Molecular Weight:

  480.45

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72 (6) :1494-503.|[3]Smith MR, et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 May 6. pii: S0302-2838 (16) 30133

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1638885-61-6]